Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Drug Discovery Today
|
July 10, 2016
Applying the best of oncology drug development paradigms to the non-malignant space
Indranil Bhattacharya, Anne Heatherington, Jeremy Barton
Expert Opinion on Pharmacotherapy
|
December 11, 2002
Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy
Gerald Batist, Jeremy Barton, Philip Chaikin, et al.
Biomolecules
|
October 2, 2019
Kinetic Transition in Amyloid Assembly as a Screening Assay for Oligomer-Selective Dyes
Jeremy Barton, D Sebastian Arias, Chamani Niyangoda, et al.
RSC Chemical Biology
|
January 3, 2022
Origin, toxicity and characteristics of two amyloid oligomer polymorphs
Chamani Niyangoda, Jeremy Barton, Nabila Bushra, et al.
Investigational New Drugs
|
January 11, 2017
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors
Geoffrey I Shapiro, Ulka N Vaishampayan, Patricia LoRusso, et al.
Blood
|
December 15, 2007
A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies
Nancy L Bartlett, Anas Younes, Matthew H Carabasi, et al.
Gynecologic Oncology
|
February 1, 2011
A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer
Katherine M Bell-McGuinn, Carolyn M Matthews, Steffan N Ho, et al.
Chemical Science
|
August 7, 2018
Origin of metastable oligomers and their effects on amyloid fibril self-assembly
Filip Hasecke, Tatiana Miti, Carlos Perez, et al.
Cancer Discovery
|
October 30, 2019
The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Jill Hallin, Lars D Engstrom, Lauren Hargis, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Drug Discovery Today
|
July 10, 2016
Applying the best of oncology drug development paradigms to the non-malignant space
Indranil Bhattacharya, Anne Heatherington, Jeremy Barton
Expert Opinion on Pharmacotherapy
|
December 11, 2002
Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy
Gerald Batist, Jeremy Barton, Philip Chaikin, et al.
Biomolecules
|
October 2, 2019
Kinetic Transition in Amyloid Assembly as a Screening Assay for Oligomer-Selective Dyes
Jeremy Barton, D Sebastian Arias, Chamani Niyangoda, et al.
RSC Chemical Biology
|
January 3, 2022
Origin, toxicity and characteristics of two amyloid oligomer polymorphs
Chamani Niyangoda, Jeremy Barton, Nabila Bushra, et al.
Investigational New Drugs
|
January 11, 2017
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors
Geoffrey I Shapiro, Ulka N Vaishampayan, Patricia LoRusso, et al.
Blood
|
December 15, 2007
A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies
Nancy L Bartlett, Anas Younes, Matthew H Carabasi, et al.
Gynecologic Oncology
|
February 1, 2011
A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer
Katherine M Bell-McGuinn, Carolyn M Matthews, Steffan N Ho, et al.
Chemical Science
|
August 7, 2018
Origin of metastable oligomers and their effects on amyloid fibril self-assembly
Filip Hasecke, Tatiana Miti, Carlos Perez, et al.
Cancer Discovery
|
October 30, 2019
The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Jill Hallin, Lars D Engstrom, Lauren Hargis, et al.
Page
of 1